Alnylam Pharmaceuticals, Inc. $805 Million Common Stock Offering
Davis Polk advised the underwriters of an $805 million SEC-registered offering of 6,440,000 shares of common stock of Alnylam Pharmaceuticals, Inc. Included in the shares are 840,000…